The rising prevalence of mental health conditions globally has fuelled the growth of digital biomarkers in the field of mental health.
As per the latest industry reports, the global market for digital biomarkers is growing, with its value estimated to reach $16,174 million by 2028. Pharma, biotech companies, and investors alike are recognising the potential benefits of continuous, passive data collection in disease detection and management.
